Comparative Pharmacology
Head-to-head clinical analysis: EPSOLAY versus SARISOL NO 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPSOLAY versus SARISOL NO 1.
EPSOLAY vs SARISOL NO. 1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EPSOLAY (ivermectin) is an antiparasitic agent derived from avermectins. It acts by binding selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions and hyperpolarization of the cell, resulting in paralysis and death of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). Ivermectin does not readily cross the blood-brain barrier in humans and has minimal affinity for mammalian ligand-gated chloride channels.
Combination analgesic and muscle relaxant; orphenadrine is a centrally acting muscle relaxant that may exert its effects via inhibition of the reticular activating system and blockade of muscarinic receptors; aspirin inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and providing analgesic and anti-inflammatory effects; caffeine is a CNS stimulant that may enhance analgesia.
Topical: Apply a pea-sized amount to the entire face once daily in the morning. Deliver 1-2 pumps to palm and apply to clean, dry face.
Butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg orally every 4 hours as needed; maximum 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 2 to 4 minutes following intravenous administration; clinically, this rapid clearance limits systemic exposure and allows for localized effect.
Terminal elimination half-life is 10-12 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion of unchanged drug (approximately 60-70% of the absorbed dose) with hepatic metabolism accounting for the remainder; fecal excretion is minimal.
Renal (70-80% as unchanged drug, 10-15% as glucuronide conjugate); biliary/fecal (5-10%)
Category C
Category C
Topical Anti-acne Agent
Topical Anti-acne Agent